Page 97 - AN-3-2
P. 97

Advanced Neurology                                          Genetics of neurodevelopmental disorders in Mexico



            NDDs overall. These figures particularly apply when   Such studies are instrumental in determining
            comprehensive exome sequencing is employed. 30     inheritance patterns, assessing the risk of recurrence, and
              In this study, we reported a high diagnostic yield,   personalizing treatments. They also facilitate the correlation
            although the sample size was small. Despite recent   of the functionality of VUS with clinical manifestations and
            revisions to the DSM and the World Health Organization’s   molecular study outcomes. Thus, advancing our molecular,
            International Classification of Diseases that aim to   genetic, and biological understanding of NDDs represents
            standardize the classification of NDDs, questions remain   a crucial step toward transforming the current model into
            regarding the clinical and biological distinctiveness of   a multidimensional, biologically informed framework for
            these disorders. This is due to diagnostic overlap and a   the prevention and management of NDDs.
            high incidence of co-occurring disorders. Consequently,   5. Conclusion
            the cases included in this study are notably heterogeneous.
            Furthermore, dysfunction in one area is accompanied by   This study underscores the complex underpinnings of
            impairments in others, resulting in multiple diagnoses.   genetic factors in the etiology of NDDs and highlights the
            The heterogeneity can also be explained with the same   indispensable role of comprehensive genetic evaluation
            underlying mechanism leading to various patterns of   in the diagnosis and management of these conditions.
            functional limitations, which justifies the presence of both   Through the detailed examination of developmental
            motor impairments and NDDs in certain patients.    disabilities within the diverse population of the Mexican
                                                               state of Jalisco, we have studied not only the prevalence and
              The genetic panels that are carefully selected based on
            clinical-genetic data, electrophysiological findings, and   unique characteristics of various NDDs but also the pivotal
            neuroimaging results can aid in etiology identification   contributions of genetic diagnostics in understanding
            and characterization of the prevalent mutations and   these disorders. Our findings advocate integrating genetic
            susceptibilities within a population. This enables the   testing into standard diagnostic protocols for NDDs,
            tailoring and enhancement of preventive programs targeted   which promises to enhance clinical outcomes through
            at  specific  genes  and  conditions  that  are  predominantly   more personalized and precise therapeutic interventions.
            carried by this group. In this study, the findings suggest a   Moreover, our research emphasizes the need for continued
            correlation with conditions such as muscular dystrophies,   exploration into the genetic basis of NDDs, aiming to
            BTD, defects in the beta-oxidation of short-chain   improve prognostic predictions, inform treatment strategies,
            fatty acids, glycosylation disorders, and mitochondrial   and support family planning decisions. Ultimately, the
            disorders,  including  those  related  to  energy  deficits  and   advancement of genetic and genomic research, combined
            cofactors such as coenzyme Q10.                    with a multidisciplinary approach to care, holds the key
                                                               to unlocking better futures for individuals with NDDs
              While deducing correlations between genetic causes   and their families, reinforcing the value of genetics in the
            of NDDs based on the presence of novel mutations in   vanguard of neurodevelopmental medicine.
            this population is feasible, it is not possible to establish
            definitive associations between these genetic factors and   Acknowledgments
            neurodevelopmental diseases without performing further
            studies. To do so, a different study design that considers the   We want to extend our heartfelt gratitude to Teresa Hernández
            VUS detected in specific cases and the role of epigenetic   López (Tita), Johanna Mariela Mora Robles, Mariana Fonseca
            factors is required.                               de La Torre, and Iveth de la Torre. Their enthusiasm and
                                                               dedication to calling us to this noble task of serving these
              The analysis of relatives is crucial to determine whether   at-risk populations in their homeland have been invaluable.
            variants are inherited or de novo, significantly enhancing   Our work has been greatly enriched by their contributions.
            the interpretative value of genetic studies. Therefore, the
            most critical role of the clinical geneticist lies in selecting   Funding
            the appropriate genetic tests and correlating the genetic   None.
            variants with clinical observations and the reported
            segregation patterns for each case.  In this study, NGS was   Conflict of interest
                                       31
            selected as the testing panel, providing highly insightful
            results regarding the clinical symptoms of patients with   The authors declare that they have no competing interests.
            NDDs and their relatives. This approach will not only   Author contributions
            shed light on causality by detecting variants or mutations
            potentially related to the disease but also aid in predicting   Conceptualization:  Norma Elena de León-Ojeda, Adonis
            genomic disorders.                                 Estévez-Perera


            Volume 3 Issue 2 (2024)                         11                               doi: 10.36922/an.3359
   92   93   94   95   96   97   98   99   100   101   102